⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432943 | 0.86 | — | — | |
| SCHEMBL1521465 | 0.77 | — | — | |
| SCHEMBL23646967 | 0.68 | — | — | |
| SCHEMBL27750636 | 0.68 | CA4 (0.33) | — | |
| SCHEMBL28625915 | 0.66 | — | — | |
| SCHEMBL29287703 | 0.64 | ELANE (0.30) | — | |
| SCHEMBL28343468 | 0.63 | — | — | |
| SCHEMBL1521464 | 0.61 | — | — | |
| SCHEMBL5475756 | 0.61 | TSHR (0.31) | — | |
| SCHEMBL19384182 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250312309-A1 | ALLYL-AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS | Mind Medicine, Inc. (US) | 2025-10-09 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025133989-A1 | SMYD MODULATORS AND USES THEREOF | ALT-BIO PTE. LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| CN-119212727-A | Targeted bifunctional degradants | 耶鲁大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4450490-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | Prazer Therapeutics Inc. (KR) | 2024-10-23 | — | — | EP | disclosed |
| CN-111771001-B | Enhanced nucleic acid polymerization by aromatic compounds | F·霍夫曼-罗氏股份公司 | 2024-09-06 | — | — | CN | disclosed |
| WO-2023212650-A1 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-2170814-A2 | ANTIBACTERIAL AGENTS | Achaogen, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-2166854-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2072522-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-24 | — | — | EP | disclosed |
| EP-2048153-A1 | SUBSTITUTED SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008156580-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| CN-1299282-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2001-06-13 | — | — | CN | disclosed |